NeuroMab™ Anti-IL-6 BBB Shuttle Antibody(NRZP-1022-ZP2904)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Humanized

Applications

In Vitro; In Vivo; Antagonist

Relevant Diseases

Neuroinflammation

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

IL-6

Official Name

IL6

Full Name

Interleukin 6 (IL-6)

Alternative Names

IL6; BSF2; HGF; HSF; IFNB2; IL-6; BSF-2; CDF; IFN-beta-2; interleukin 6

Product Pictures

FuncS

Figure 1 depicts mean plasma CRP concentrations following a single intravenous injection in patients with advanced cancer. Ab1 (ALD518) was infused at 80, 160 or 320 mg (n=8).

FuncS

Figure 2 depicts mean serum CRP levels in rheumatoid arthritis patients with an inadequate response to methotrexate following administration of 80, 160, or 320 mg of Ab1(ALD518).

FuncS

Figure 3 shows that Ab1 increased mean hemoglobin concentration (g/dL) by 80, 160 and 320 mg after 12 weeks of administration in NSCLC patients compared to placebo.

FuncS

Figure 4 depicts Ab1 increasing mean albumin concentrations at 80, 160 and 320 mg in NSCLC patients.

FuncS

Figure 5 graphically illustrates the mean change in SF-36 composite score at week 12 in a phase II clinical trial of ALD518 administered to patients with active RA.

FuncS

Figure 6 depicts the relationship between WHO oral mucositis grade and cumulative IMRT (Gy): Three patients received ALD518 160 mg intravenously at weeks 0 and 4.

Publications